Immuneering Corporation (IMRX) shares surged 47.55% in after-hours trading to $2.11, following a 10.85% increase to close at $1.43 on September 12, 2024. The significant after-hours jump was driven by the announcement of positive initial data from the company's Phase 2a clinical trial. The trial is evaluating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. The initial results showed a 40% overall response rate and an 80% disease control rate among the first five patients, with two patients achieving complete or partial responses. These promising results, which exceed the benchmarks for gemcitabine/nab-paclitaxel alone, have sparked investor optimism about the potential of IMM-1-104 in improving treatment outcomes for pancreatic cancer. The company also noted that the treatment was well-tolerated, and further patient enrollment at a higher dose has been approved, indicating a clear path forward for the drug's clinical development.